Targeting a neoantigen derived from a common TP53 mutation

TP53 (tumor protein p53) is the most commonly mutated cancer driver gene, but drugs that target mutant tumor suppressor genes, such as TP53, are not yet available. Here, we describe the identification of an antibody highly specific to the most common TP53 mutation (R175H, in which arginine at positi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Science
Main Authors: Hsiue, Emily Han-Chung, Wright, Katharine M., Douglass, Jacqueline, Hwang, Michael S., Mog, Brian J., Pearlman, Alexander H., Paul, Suman, DiNapoli, Sarah R., Konig, Maximilian F., Wang, Qing, Schaefer, Annika, Miller, Michelle S., Skora, Andrew D., Azurmendi, P. Aitana, Murphy, Michael B., Liu, Qiang, Watson, Evangeline, Li, Yana, Pardoll, Drew M., Bettegowda, Chetan, Papadopoulos, Nickolas, Kinzler, Kenneth W., Vogelstein, Bert, Gabelli, Sandra B., Zhou, Shibin
Formato: Artigo
Idioma:Inglês
Publicado em: 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8208645/
https://ncbi.nlm.nih.gov/pubmed/33649166
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/science.abc8697
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados